Genomic Expression

From mRNA to Cure
By analyzing RNA we can detect disease, monitor health, and design Next Generation Cures

Our OneRNA platform enables repurposing of existing drugs on an individual patient basis and the development of individualized novel RNA therapeutics e.g. RNA vaccines to develop Next Generation Cures.

Learn More

ARE YOU A DOCTOR OR A PATIENT ?
Looking for better treatment options for your patients? Our OneRNA Platform enables repurposing existing drugs on an individual patient basis

Learn More

ARE YOU DEVELOPING CURES?
Using just one biomarker can save $1B during clinical development.
The OneRNA Platform makes the companion diagnostic into an algorithm and rapidly translates RNA code to novel RNA Theraputics

Learn more
RNA Platform
By analyzing RNA we can monitor health, detect disease and design next generation cures

DNA is not your fate. RNA is coding for proteins and proteins are targets for drugs, today RNA is directly a target for drugs and a drug itself. We are experts in analyzing RNA using Next Generation Sequencing and translating RNA Code to RNA Therapeutics to individualize treatment

OneRNA® for treatment selection in cancer
Click here to learn more
DNA is not your fate. RNA codes for proteins and proteins are targets for drugs, furthermore today RNA is directly a target for drugs and a drug itself. We coded all that information into our OneRNA® platform and initiated 3 clinical studies to produce supporting data.
WHO WE ARE
Experienced Management Team with Startup RNA

Gitte Pedersen
CEO and co-founder
Gitte Pedersen, CEO is a former executive at NovoZymes, the world’s largest enzyme manufacturer. She has advised the Danish Government and early stage biotech companies regarding their corporate development in the US

Follow at DNABARCODE
Morten Pedersen
CSO and cofounder
Morten Pedersen, CTO and co-founder holds a Ph.D in genomics. He has a very strong innovation track record with multiple key patents in genomics. Morten is the inventor of Genomic Expression’s sample prep technologies

Jesper Zeuthen
VP Oncology research
Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had IPOs), and prior to that he established one of the laboratories that became the Danish Cancer Society.
WHO'S TALKING ABOUT US
We have been featured in Forbes twice, GEN, GenomeWeb and MedWatch. Our investors include Biogen founders, Harvard Business Angels, Investor Circle, Pipeline Angels, and a family office; Centurion Holding in New York.

We are a Springboard alum company and among the 500 women-owned technology companies they have supported. Genomic Expression came in #2 in the Women’s Founders Pitch event in LA, was in the top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Technology Challenge, and was invited to dinner with Branson on Necker’s Island.

We have brought the company from idea to commercialization for grants, revenue, and angel funding, and are now implementing capabilities to rapidly translate RNA code to novel RNA Theraputics in collaborations with Biotech and Pharma

This is our founder's story:
Articles, Grants, Investors and Customers
These are our supporters, funders and customers

Grant
Genome Danmark
Accelerator
Impact Investor
Investor
Impact Investor
#2 at WFN
Top 10 XTC
Horizon2020 grant
Eurostars Grant
MedTech Innovator Top 50
Winner of the Lyfebulb-Helsinn Award
Winner of the EIC Lifescience Award
Featured in Forbes
Won EUTop50 and invited to present at the European Parliament
Presented at GSTIC addressing the UN sustainability goals in health
Finals of the Blue Cross Blue Shields GuideWell competition for novel COVID19 solutions
In the semi-finals of the XPRIZE for Rapid Covid Testing - $6 million dollar, 6-month competition to develop faster, cheaper, and easier to COVID-19 testing methods at scale.
XPrize Semifinalist Targets 300 Million Tests Per Day With Scalable COVID Self-Test
WANT TO LEARN MORE ?
DISCLAIMER
The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting-in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.
YOU + SOCIAL MEDIA
= SOCIAL IMPACT
You're awesome. Let's talk.

From mRNA to Cure

By analyzing RNA we can detect disease, monitor health, and design Next Generation Cures

ARE YOU A DOCTOR OR A PATIENT ?

Looking for better treatment options for your patients? Our OneRNA Platform enables repurposing existing drugs on an individual patient basis

ARE YOU DEVELOPING CURES?

Using just one biomarker can save $1B during clinical development. The OneRNA Platform makes the companion diagnostic into an algorithm and rapidly translates RNA code to novel RNA Theraputics

RNA Platform

OneRNA® for treatment selection in cancer

Click here to learn more

WHO WE ARE

Experienced Management Team with Startup RNA

Gitte Pedersen

CEO and co-founder

Morten Pedersen

CSO and cofounder

Jesper Zeuthen

VP Oncology research

WHO'S TALKING ABOUT US

Articles, Grants, Investors and Customers

These are our supporters, funders and customers

WANT TO LEARN MORE ?

YOU + SOCIAL MEDIA= SOCIAL IMPACT

You're awesome. Let's talk.

Using just one biomarker can save $1B during clinical development.
The OneRNA Platform makes the companion diagnostic into an algorithm and rapidly translates RNA code to novel RNA Theraputics

YOU + SOCIAL MEDIA
= SOCIAL IMPACT